Clinical trials: Pancreatic Cancer
Non-colorectal Cancer, Pancreatic Cancer
Maytansinoid DM4-Conjugated Humanized Monoclonal Antibody huC242 in Treating Patients With Solid Tumors
RATIONALE: Monoclonal antibodies, such as maytansinoid DM4-conjugated humanized monoclonal antibody huC242, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00352131
- Testing
- HuC242-DM4
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- ImmunoGen, Inc.
Breast Cancer, Colorectal Cancer
Phase I Study of CDX-1307, hCG-B Vaccine, for Patients With Incurable, Locally Advanced or Metastatic Breast, Colorectal, Pancreatic, Bladder or Ovarian Cancer
This research study is for individuals who have advanced breast, colon, pancreatic, ovarian or bladder cancer. Celldex Therapeutics, Inc.
- Conditions
- Breast Cancer, Colorectal Cancer, Pancreatic Cancer, Bladder Cancer
- Trial name
- CDX1307-02 (NCT00648102)
- Testing
- CDX-1307
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Celldex Therapeutics
Solid Tumors
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
The purpose of this study is to evaluate the efficacy and safety of standard chemotherapy with or without INCB161734 in participants with metastatic pancreatic ductal adenocarcinoma (PDAC).
- Trial name
- DAWN-303 (NCT07522073)
- Testing
- INCB161734, Investigator's choice of chemotherapy
- Where
- 230 sites in United States, Australia and 20 more
- Volunteers
- 588 people
- Sponsor
- Incyte Corporation
Pancreatic Cancer, Ductal Adenocarcinoma of the Pancreas
Study of SBP-101 in Pancreatic Cancer
This phase 1 first-in-human study evaluates safety and tolerability of SBP-101 in subjects with previously treated pancreatic ductal adenocarcinoma and will identify the maximum tolerated dose (MTD).
- Trial name
- NCT02657330
- Testing
- SBP-101
- Where
- 4 sites in United States, Australia
- Volunteers
- 29 people
- Sponsor
- Panbela Therapeutics, Inc.
Lung Cancer, Breast Cancer
Dose Escalation Trial of 2-Deoxy-D-Glucose (2DG) in Subjects With Advanced Solid Tumors
The objectives of this study are to evaluate the safety, tolerability, pharmacokinetics, and biologic effect (FDG PET, preliminary efficacy) of daily oral doses of 2DG with and without weekly docetaxel in subjects with advanced…
- Conditions
- Lung Cancer, Breast Cancer, Pancreatic Cancer, Head and Neck Cancer
- Trial name
- NCT00096707
- Testing
- 2-deoxy-D-glucose (2DG)
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Threshold Pharmaceuticals
Advanced Solid Tumors, NSCLC Adenocarcinoma
A Study of MGC028 in Participants With Advanced Solid Tumors
The goal of this clinical trial is to characterize the safety, tolerability, dose-limiting toxicities (DLT), and maximum tolerated dose (MTD) or maximum administered dose of MGC028 (if no MTD is defined).
- Conditions
- Advanced Solid Tumors, NSCLC Adenocarcinoma, Cholangiocarcinoma, Pancreatic Carcinoma
- Trial name
- NCT06723236
- Testing
- MGC028
- Where
- 7 sites in United States
- Volunteers
- 124 people
- Sponsor
- MacroGenics
Pancreatic Adenocarcinoma, Non Small Cell Lung Cancer
A Phase Ⅰ Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma
This is a phase I, open-label, first-in-human study of CS08399, comprising two phases: dose escalation (including single-dose and multiple-dose) and cohort expansion.
- Conditions
- Pancreatic Adenocarcinoma, Non Small Cell Lung Cancer, Advanced Solid Tumors, Lymphoma
- Trial name
- NCT07583771
- Testing
- CS08399
- Where
- China
- Volunteers
- 186 people
- Sponsor
- Chipscreen Biosciences, Ltd.
Advanced Malignant Solid Neoplasm, RAS Mutation
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
RSC-101 is a Phase 1a/1b clinical trial of RSC-1255 in adult study participants with advanced solid tumor malignancies who are intolerant of existing therapies known to provide clinical benefit, have disease that has progressed…
- Conditions
- Advanced Malignant Solid Neoplasm, RAS Mutation, Lung Cancer, Colon Cancer
- Trial name
- NCT04678648
- Testing
- RSC-1255 Dose Escalation, RSC-1255 Dose Expansion
- Where
- 3 sites in United States
- Volunteers
- 134 people
- Sponsor
- RasCal Therapeutics, Inc.
Pancreatic Cancer
A Phase II Trial of TPI 287 in Patients Advanced, Unresectable Pancreatic Cancer
The primary objective of the study is to assess the activity of TPI 287 as single agent therapy for patients with advanced, unresectable pancreatic cancer after failure of gemcitabine-containing therapy.
- Trial name
- NCT00553813
- Testing
- TPI 287
- Where
- 4 sites in United States, Spain
- Volunteers
- 23 people
- Sponsor
- Cortice Biosciences, Inc.
Pancreatic Cancer
Stereotactic Adaptive Radiation Therapy of Borderline Resectable Pancreatic Cancer an Individualized Approach
This trial is a single-arm, prospective, multi-center clinical trial designed to demonstrate that stereotactic adaptive radiotherapy using an ablatively dosed (50Gy,5fx) for treatment of borderline-resectable, locally-advanced …
- Trial name
- ARTIA-Pancreas (NCT05764720)
- Testing
- Daily Adaptive External Beam Radiation Therapy
- Where
- 4 sites in United States
- Volunteers
- 134 people
- Sponsor
- Varian, a Siemens Healthineers Company
Non Small Cell Lung Cancer, Colorectal Cancer
FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
This is a Phase 1 dose-finding study of FT536 given in combination with a monoclonal antibody following lymphodepletion in participants with advanced solid tumors.
- Conditions
- Non Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer
- Trial name
- NCT05395052
- Testing
- FT536, Cyclophosphamide, Fludarabine
- Where
- 5 sites in United States
- Volunteers
- 5 people
- Sponsor
- Fate Therapeutics
Locally Advanced Malignant Neoplasm, Malignant Solid Tumour
A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors
This is a Phase I, open-label, multi-center, competitive enrollment and dose-escalation study of ALT-836 in combination with standard of care gemcitabine in participants who have locally advanced or metastatic solid tumors.
- Trial name
- NCT01325558
- Testing
- ALT-836 in combination with gemcitabine
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Altor BioScience
Pancreatic Cancer
ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study
A Phase I open label followed by a Phase II randomized, controlled study to assess the efficacy and safety of ABTL0812 in combination with FOLFIRINOX for first-line treatment of metastatic pancreatic.
- Trial name
- PanC-ASAP (NCT04431258)
- Testing
- ABTL0812, Folfirinox
- Where
- 24 sites in United States, France and 2 more
- Volunteers
- 150 people
- Sponsor
- Ability Pharmaceuticals SL
Non-Small Cell Lung Cancer, Renal Cell Cancer
CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
This is a Phase 1/1b open-label, dose escalation and dose expansion study of CPI-006, a humanized monoclonal antibody (mAb) targeting the CD73 cell-surface ectonucleotidase in adult subjects with select advanced cancers.
- Conditions
- Non-Small Cell Lung Cancer, Renal Cell Cancer, Colorectal Cancer, Triple Negative Breast Cancer
- Trial name
- NCT03454451
- Testing
- CPI-006, CPI-006 + ciforadenant, CPI-006 + pembrolizumab
- Where
- 27 sites in United States, Australia
- Volunteers
- 117 people
- Sponsor
- Corvus Pharmaceuticals, Inc.
Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
The LINFU® U.S. Registry for the in the General Population Without Risk Factors
Adenocyte has developed LINFU®, (Low Intensity Non-Focused Ultrasound excitation of the pancreas) as a method of identifying early, asymptomatic pancreatic cancer and its noninvasive precancerous lesions..
- Conditions
- Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Pancreatic Dysplasia
- Trial name
- NCT06276803
- Testing
- LINFU®
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Adenocyte, LLC
Ovarian Cancer, Endometrial Cancer
HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors
This is a data collection study, also referred to as a "screening" study; no investigational or standard therapy will be administered as part of this study.
- Conditions
- Ovarian Cancer, Endometrial Cancer, Colo-rectal Cancer, Cholangiocarcinoma
- Trial name
- NCT05124743
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Alaunos Therapeutics
Advanced Pancreatic Adenocarcinoma
A Trial of Y101D in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Advanced Pancreatic Cancer
The Phase Ib/II study is an open-label, single-arm, multicenter trial designed to assess the efficacy and safety of Y101D in combination with Gemcitabine and Albumin Paclitaxel as first-line systemic treatment for advanced…
- Trial name
- NCT06266143
- Testing
- Y101D
- Where
- China
- Volunteers
- 71 people
- Sponsor
- Wuhan YZY Biopharma Co., Ltd.
Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
This is a nonrandomized, uncontrolled, open-label, multicenter Phase 2 study to evaluate the efficacy, safety, and tolerability of futibatinib in combination with PD-1 antibody-based SoC therapy in adult patients with solid…
- Conditions
- Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer, Siewert Type 1 GEJ Cancer
- Trial name
- NCT05945823
- Testing
- Futibatinib, Pembrolizumab, Cisplatin
- Where
- 22 sites in United States, France and 2 more
- Volunteers
- 53 people
- Sponsor
- Taiho Oncology, Inc.
Solid Tumor, Adult, Solid Tumor
A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression
The goal of this study is to test A2B530,an autologous logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), and other…
- Conditions
- Solid Tumor, Adult, Solid Tumor, Pancreatic Cancer, Pancreatic Neoplasms
- Trial name
- EVEREST-1 (NCT05736731)
- Testing
- A2B530, xT-Onco with HLA-LOH Assay
- Where
- 8 sites in United States
- Volunteers
- 160 people
- Sponsor
- A2 Biotherapeutics Inc.
Epithelial Tumors, Malignant
Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors
MYE Symphony is a multicenter, open-label, Phase 1 first-in-human study to assess the safety, tolerability, and define the RP2D of MT-302 in participants with advanced epithelial cancer.
- Trial name
- MYE Symphony (NCT05969041)
- Testing
- MT-302 (A)
- Where
- 6 sites in Australia
- Volunteers
- 48 people
- Sponsor
- Myeloid Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.